Dr. David Coe is the co-founder and CEO of CoED Biosciences, he previously held senior roles at Cytoseek, Queen Mary University and Imperial College. With a PhD in tumour immunology from Imperial College London, Dr. Coe furthered his expertise in making and directing cell therapies with post-doc experience at Imperial College, Queen Mary University and Bristol University. Dr Coe’s research focused on understanding the role of T cell migration in transplantation rejection, immune tolerance, myocarditis and cancer. He has a history of completing pre-clinical projects where tissue targeted cells are fundamental to success. David is now leveraging his business and leadership skills to build CoED Biosciences into an innovation leader that can deliver new treatment options to patients around the world.